🔗 Share this article

While America undertakes historic changes to its vaccination schedules, a particular individual has surfaced unexpectedly: Høeg, a US-based physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines throughout the global health crisis and has focused upon potential deaths after Covid immunization in her short time at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Agency leaders had intended to reveal radical revisions to the childhood vaccine schedule earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US at odds with much of the global community with no evidence for public health gain. The planned update has been pushed back until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to head the division this calendar year.

A Shift at the FDA

The acting appointment may indicate a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has repeatedly called for ending specific pediatric vaccine recommendations in the US so as to align more like Denmark, a society with nationalized medicine and a population roughly the population of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Background

Dr. Høeg has no obvious background in medication creation, oversight or administrative roles, which has been customary for previous heads of the CBER. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous directors of CBER would “grasp regulatory frameworks and the science of drug development”, commented Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

This division has an enormous portfolio at the FDA, Woodcock emphasized.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these have to be managed,” she said. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a significant administrative element to the position, which supervises over 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” Woodcock added.

Agency Reaction and Controversial Policies

Regarding questions about Høeg’s fitness for the role and whether this selection represents greater collaboration among FDA leaders on vaccines, a representative stated that the “concerns are based on incorrect premises”.

“Her experience is consistent with the duties of her position,” the representative stated, citing the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial one-day therapy clearance system that allegedly troubled her preceding directors. “By what process are these drugs being picked for this fast-track system? Who takes the decisions?” Howard said. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards laxer oversight of most medications, aside from shots.”

Documented Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if problematic, history, critics have noted. She authored a study using unverified crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the new government included revising regulations for novel immunizations and discontinuing “unnecessary” immunizations, she said following the vote on a audio program. At the FDA, Høeg has reportedly suggested preventing young men from receiving COVID-19 vaccines.

“She is an complete dogmatist who begins with her preconceived notions and works backwards to retrofit the data in a extremely misleading, dishonest way,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow dissenters, {like|